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1.0 INTRODUCTION 
1.1 EPIDEMIOLOGY  
1.1.1 PROSTATE CANCER AND RISK FACTORS 
Prostate cancer (CaP) is the most common non-skin cancer and the second most 
common cause of cancer death in Norwegian men (1). In 2009, 4299 new cases of 
CaP were recorded and 1048 died of CaP in Norway. The established risk factors 
of CaP are age, ethnic origin, heredity and geographic localization (2). There might 
be a weak association between obesity and CaP (3). Socioeconomic status has 
been a suggested risk factor, although unequal general health care among groups 
of residents may explain the difference (4). Occupation does not seem to be a risk 
factor in CaP (5).  
 
1.1.2 PROSTATE CANCER EPIDEMIOLOGY 
The earliest reliable cancer registries and epidemiological studies 40 years ago 
showed a distinct 40-fold difference in the incidence of CaP between U.S. African 
and native Japanese men (6). Latest registry data during 1998 to 2002 from the 
International Agency for Research on Cancer (IARC) show even higher differences 
(7). Figure 1 shows the CaP incidence per 100.000 men at 60 years of age in 
various countries around the globe. At 60 years of age, 1 % of U.S. black men will 
be diagnosed with CaP, while 0.5 % of Western European men, 0.025 to 0.1 % of 
Japanese men and 0.005 % of North-East Chinese men are diagnosed having the 
disease. The maximal difference is therefore 200-fold. There are also ethnic 
differences within the same region, like the higher incidence at 0.2 % for Israeli 
Jews as opposed to surrounding ethnicities which have incidence rates 4 to 10-fold 
lower. There are differences between countries having the same ethnic population, 
like a 2-3 fold lower incidence in Denmark compared to the rest of the Scandinavian 
countries, although the mortality rates are the same (8). When Chinese and 
Japanese men migrate to U.S., the incidence of CaP will increase to about half of 
that of the Caucasian population (7). The lifetime risk of a newborn today to be 
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diagnosed with CaP is for an U.S. Black 19.10 %, an U.S. White 16.48 %, an U.S. 
Asian 11.46 % and a Norwegian 12.7 % (1, 9). 
 
 
 
 
 
 
 
 
 
 
Figure 1. Incidence of prostate cancer per 100 000 at 60 years of age. 
 
1.1.3 SOY CONSUMPTION AND PROSTATE CANCER 
High plasma levels of genistein have been found in men living in areas with 
decreased risk for CaP, whereas low levels are found in areas with increased risk. 
The difference in genistein levels may be more than 100-fold (10-12). Several 
studies have established an association between decreased CaP risk and high soy 
consumption or genistein plasma levels. In a cohort of 7999 men of Japanese 
ancestry in Hawaii observed from 1965 through 1986, increased tofu intake was 
associated with decreased risk of CaP (13). A later study on 5826 of these men 
concluded that the relative risk (RR) was 0.8 comparing high and low consumers of 
tofu, but it was not statistically significant (14). The Adventist Health Study in the 
U.S. (12,395 men) showed that once a day consumers of soy milk had a significant 
40% reduced incidence of CaP while those who had several servings of soy milk 
daily had a 70% reduction, although it was not statistical significant (15). In the 
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Japanese Life Span Study cohort in Hiroshima and Nagasaki on 18115 men, total 
soy consumption was associated with a 20 % non-significant decrease of CaP (16). 
In the Japan Public Health Center–Based Prospective Study on 43509 men, a 
significant decrease of CaP risk (RR=0.52) in the highest compared to lowest 
consumers of soy food was reported (17). In a prospective nested case control 
study on 950 cases and 1042 controls participating in the European Prospective 
Investigation into Cancer and Nutrition (EPIC), a significant decreased risk 
(RR=0.74) of CaP was found in men with the highest circulating levels of genistein 
compared to the lowest (18).  
 
1.1.4 URGENCY TO PREVENT CAP 
The economic burden of CaP diagnosis and treatment, by drugs, radiation or 
surgery, is high in Western high endemic countries. Over- and under treatments of 
CaP are concerning issues (19). Although CaP occurs mainly in old age, most men 
receiving the diagnosis are still productive and the psychological effects may be 
devastating in respect to social life, family and work. The number of patients having 
CaP is expected to double or maybe even triple within the next decade in Western 
countries (20). It is therefore urgent not only to improve diagnosis and treatment of 
the disease, but also to improve and intensify preventive measures. There is strong 
epidemiological support for one or several environmental factors increasing or 
reducing the risk of CaP in a regional male population.  
 Currently, there is no highly specific CaP biomarker, which expression would 
be related to the aggressiveness of the disease. However, the level of prostate 
specific antigen (PSA) in blood gives a good indication of tumor load and 
progression when the disease has been diagnosed. PSA velocity has been 
significantly associated with outcome (21).  
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1.2 NUTRITION AND CANCER 
1.2.1 CHEMOPREVENTION 
Chemoprevention of cancer is the ability of certain molecules to inhibit (partially or 
totally) induction or progression of the disease. Ideally the molecule should be 
easily accessible, cheap, non-toxic and have a measurable clinical effect. 
Preferably it should be part of the normal nutrition in natural or enriched food. The 
hypothetical mechanisms of chemoprevention include that the agent; 1) acts as an 
anti-hormone and modulates hormonal receptors, e.g. tamoxifen in estrogen-
dependent breast cancers, 2) acts as an anti-oxidant, thus reducing the damage on 
the genome by free radicals and relieving the cells own DNA repair machinery and 
3) acts directly on intra-cellular signaling pathways, e.g. on important junctions for 
growth signaling like Akt/protein kinase B (PKB). A number of substances with all or 
some of these properties have been identified. During the last 30 years the basic 
and clinical research on the chemopreventive properties of these molecules has 
increased. Theoretically, CaP is a suitable target for chemoprevention due to the 
long latency of the disease and the usually slow progressive development into more 
aggressive stages. 
 
1.2.2 NUTRITION AND PREVALENCE OF CANCER  
Most people would recognize that there is a connection between what we eat and 
the prevalence of cancer, although we cannot estimate accurately the proportion of 
cancer attributed to nutrition factors. The reason for this is that we in most cases 
still don’t know the causative agents. Even harder is the identification of protective 
agents. However, we know that acrylamide, a possible carcinogen, may be present 
in relative high concentrations in some prepared foods like French fries, although 
the epidemiological evidence is lacking for most cancers, except for a small risk 
increase in kidney cancer (22, 23). Nitrite, which is used for preservation in foods, is 
associated with stomach and esophageal cancer (24). Aflatoxin is associated with 
hepatocellular cancer (25). Also, some more or less diffuse connections between 
nutrition and cancer are known, e.g. obesity, energy intake, red meat, hot food and 
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alcohol (26). In a review in 1981, Doll and Peto concluded that their best estimate 
was that 35 % of cancer deaths were attributed to diet factors and that the range of 
acceptable estimates was 10-70 % (6). 
 
1.2.3 NUTRITION AND PROSTATE CANCER 
As mentioned above, CaP is a good target for chemoprevention due to the long 
latency and slow progression of the disease, at least during the initial stages. The 
identification of protective agents is very difficult, due to the obvious small potency 
of agents that are supposed to fulfill the criteria of chemoprevention, foremost to be 
non-toxic during life-time use. Epidemiological studies are perhaps the strongest 
proof for the effects by these agents, although both molecular mechanisms and 
clinical trials are necessary to verify the evidence. It is not within the scope of this 
thesis to discuss all promising chemopreventive agents related to CaP. However, 
some should be mentioned. Resveratrol, a polyphenol, which is present in the skin 
of grapes has several similar molecular effects to genistein (27). It also has an 
epidemiological support by the lower incidence of CaP in the Mediterranean area 
compared to Northern Europe. Clinical studies are ongoing. The effects of Vitamin 
D are also supported by a South vs. North epidemiological difference, in addition to 
potent molecular effects (28). However, the toxicity in its present form makes it 
unsuitable as a chemopreventive agent. Lycopene, the red pigment in tomatoes, 
has a strong anti-oxidant activity and is also supported by North vs. South 
epidemiology (29). The effects of selenium, a mineral with a relatively high risk of 
toxicity, which is necessary for vital cellular functions, are supported by its anti-
oxidant properties and by a phase II randomized clinical controlled trial (RCT) 
primarily investigating skin cancer, which showed a significantly less (RR 0.37) 
incidence of CaP (30). However, the phase III clinical trial, Selenium and Vitamin E 
Cancer Prevention Trial (SELECT) in the U.S. including more than 35.000 
participants during 7 years of intervention with selenium, did not detect any 
significant benefit (31). Surprisingly, later analysis of its results shows that 
intervention with Vitamin E, a proposed anti-oxidant, induces a 17% statistically 
significant increase in CaP (32). In the Finnish Alpha-Tocopherol Beta-Carotene 
Cancer Prevention Study (ATBC), which primarily investigated the 
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chemoprevention of lung cancer in almost 30.000 male smokers, Vitamin E 
intervention resulted in 34 % lower incidence of CaP (33). These findings illustrate 
the difficulties in identifying the protective agents in cancer and the need for 
thorough epidemiological, molecular and smaller clinical intervention trials before 
venturing into large phase III/IV studies.  
 
1.3 CANCER 
1.3.1 BACKGROUND 
Cancer is a common term for diseases caused by abnormal cells that grow without 
control and that are able to invade surrounding tissue. Figure 2 illustrates two ways 
of describing cancer, either by a chain of events or by biological capabilities. 
Cancer starts with subtle molecular changes before manifesting clinically, often 
spanning over many years. The following chain of events are suggested; 1) 
inflammation, which may create the prime setting for cancer, 2) premalignant cells, 
which with high probability will develop into malignant cells and 3) metastases, 
which represents the final and most advanced stage of cancer. These have also 
been the suggested targets of chemoprevention (34). Cancer may also be 
described as a collection of hallmarks of biological capabilities, which gives a more 
complex picture; 1) inducing angiogenesis, resulting in vascularization of the 
neoplastic cells. 2) evading growth or tumor suppressors, which may inhibit the cell 
cycle. 3) enabling replicative immortality by regeneration of DNA ends. 4) activating 
invasion and metastasis by a complex series of events, including cell to cell and cell 
to matrix interactions. 5) reprogramming of energy metabolism, shifting towards 
glycolysis producing lactate and becoming less sensitive towards hypoxic 
conditions. 6) sustaining proliferative signaling. 7) evading immune destruction and 
8) resisting cell death (35). Increased mutability and inflammation may act as 
enabling characteristics in the progression of cancer.  
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Figure 2. Cancer as a chain of events or biological hallmarks, including the 
enabling characteristics on top. 
 
1.3.2 PROSTATE CANCER AND ANDROGENS 
Since the 1940s pioneering and Nobel prize award winning work by Charles 
Huggins, androgens have been recognized as an important factor in CaP 
progression. Androgen depletion, either by orchiectomy or drugs, still stands as the 
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first line of treatment of advanced CaP (36). The androgens and the androgen 
receptor (AR) are important for prostate development and function, and AR positive 
cells are found both within the glands and the surrounding stroma. The AR gene is 
located on the X chromosome (37). It belongs to the nuclear receptor superfamily, 
which ligand-activated transcription factors are classified into three groups 
depending on the chemical property of their ligands, steroid, non-steroid or orphan 
(38). The AR is part of the steroid receptor subfamily and forms homodimers during 
activation. The structural composition of nuclear receptors contains an amino-
terminal domain (NTD), a DNA-binding domain (DBD), a hinge region and a ligand 
binding domain (LBD). More than 100 cellular proteins, including co-activators and 
co-repressors that regulate AR function, have so far been identified (Nuclear 
Receptor Signaling Atlas (NURSA)). It was early recognized that not all advanced 
cases of CaP were sensitive to androgen depletion and that most CaP cells after a 
few years will become insensitive to androgen depletion treatment (development of 
castration resistant prostate cancer (CRPC)). It is still unknown how the CaP cells 
acquire this refractory trait, but the androgen signaling pathway seems to play an 
important role in most cases as mutations in the AR, changes in the activity of its 
cofactors, up-regulation of steroidogenesis and ligand independency are often 
observed (39).  
 
1.3.3 MORPHOLOGICAL CHANGES IN THE PROGRESSION OF CAP  
Several descriptive methods of the morphological changes in the progression of 
CaP have been developed and extended during the last decades. The top part of 
figure 3 illustrates 3 morphological methods of describing the progression of CaP, 
without any internal spatial specificity or temporal similarities between the methods. 
The simplest is to regard a transition from the normal epithelium to proliferative 
inflammatory atrophy (PIA), as a possible result of hormonal changes, physical 
trauma, viral, bacterial and/or oxidative damage (40). PIA has been observed in 
close relation to prostatic intraepithelial neoplasia (PIN), High grade PIN (HGPIN) 
and CaP. PIN is characterized by several cytological characteristics and HGPIN by 
further distinct characteristics, closely resembling those of CaP, like larger nuclei 
and increased chromatin content (41). Several molecular changes, like 
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chromosomal deletions, are also frequent both in HGPIN and CaP. It is somewhat 
controversial whether latent CaP is a special entity in the progression of CaP with 
not fully developed and senescent malignancy or if it simply is a developing CaP 
(42). Especially older autopsy materials revealed that many men in old age had 
prostate lesions resembling CaP, without being clinical apparent, indicating a 
prevalence of almost 40 % in 50 years old men (43). However, more recent studies 
have reported less than 1 % prevalence in 50 years old men (44). Symptomatic 
clinical CaP may present itself by lower urinary tract symptoms (LUTS), including 
urgency, obstruction, hematuria and infection. A tumor in the prostate may be 
palpable by digital rectal examination. The diagnosis is histologically verified by 
needle or resection biopsy. The final stage is metastases, nearly always first to 
regional lymph nodes and bone, although it may metastasize to other organs such 
as lung, liver, pleura, adrenal glands and brain (45, 46).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Morphologic and gene expression changes in the progression of 
CaP. 
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Gleason score  
The Gleason grading and scoring system is based on morphologic glandular 
changes in the progression of CaP. The scoring is composed of a major primary 
grade and a secondary grade from 1 to 5. The grades 1 and 2 are rarely used as 
they can hardly be discriminated from normal glands (47). An additionally higher 
tertiary grade is sometimes used, although it is debated whether it is a factor of 
prognostic significance. Gleason grade 3 is the most common in CaP and is 
considered as well-differentiated. The glands may differ in size and some cells are 
invading the stroma, but each gland is surrounded by stroma. Gleason grade 4 is 
important as patients harboring this grade have a worse prognosis. The glands no 
longer form separate units with lumen and surrounding stroma. Gleason grading is 
widely used and is a strong prognostic parameter in CaP. 
TNM-staging 
The TNM-staging system of CaP represents the primary tumor load (T), presence 
of regional lymph node involvement (N) and distal organ metastasis (M) (48). At 
stage T1, the tumor is not clinically apparent and further divided into (a) and (b) for 
resected material and (c) for needle biopsy. At stage T2, the tumor is confined 
within the prostate and it is further divided into a, b and c depending on its 
involvement area of the prostate. At stage T3, the tumor extends through the 
prostate capsule and it is further divided into a and b depending on involvement of 
the seminal vesicles. At stage T4, the tumor is locally advanced and invades 
adjacent organ structures. The M stage (distal organ metastases) is divided into M0 
(no distal metastases) and M1 (distal metastases), which is further divided into M1a 
(non-regional lymph nodes), M1b (bone) and M1c (other sites with or without bone). 
The TNM system is regularly revised and changes are likely to be proposed during 
coming years. 
 
1.3.4 GENE EXPRESSION CHANGES IN THE PROGRESSION OF CAP  
In addition to the close relation between CaP and androgens, the last decades of 
research have uncovered several gene expression changes. Some of these are 
appearing quite early in the progression of CaP, whereas others appear late. 
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However, the temporal relationship of the events and their significance regarding 
the development of CaP are mostly unknown (49). Those associated with our 
studies will be mentioned. The lower part of figure 3 illustrates the gene expression 
changes in relation to the progression of CaP, although the temporal and spatial 
differences in general still are uncertain. The changes will be detailed in the 
following chapters. 
Androgen related genes 
The androgen regulated genes (ARGs) represent a large group of genes connected 
to the AR by having an androgen response element (ARE), a conserved short DNA 
sequence matching the DNA binding site of the AR, in their promoters. Androgens 
regulate growth and differentiation of the human prostate. This is also mimicked at 
the gene level as AR-responsive genes linked to differentiation and cell cycle 
regulation are regulated as well as genes encoding enzymes of metabolic 
pathways. The expression of the AR itself is decreased with increasing Gleason 
grade (50). However, AR expression remains in most CaP and increases in CRPC 
compared to hormone sensitive CaP (51). 
The androgen related gene expression changes appear mainly quite early in 
the progression of CaP. Among the best known ARGs are prostate specific antigen 
(PSA), also known as kallikrein 3, and NK3 homeobox 1 (NKX3.1). NKX3.1 is one 
of the earliest markers of prostatic luminal cells and is a suggested tumor 
suppressor in CaP (52, 53). Up to 60-80% NKX3.1 loss of heterozygosity has been 
reported in high grade CaP, although it also appears to a lesser degree in PIN (54, 
55). However, although the nuclear protein expression of NKX3.1 is reduced in 
early CaP and continues to decrease with progressing CaP, it is not completely 
absent even in metastatic CaP (56). PSA is a widely used and the most important 
prognostic biomarker in CaP. Its main function is to liquefy the prostatic fluid by its 
serine protease activity and it is produced by differentiated luminal cells of the 
prostate. Although the serum level of PSA is increased during the progression of 
CaP, the intra-cellular expression of PSA is reduced with increasing Gleason grade 
(57). Kallikrein 4 (KLK4), encoding a serine protease neighboring KLK3 on 
chromosome 19, is also an AR target gene. In contrast to the genes mentioned 
above, KLK4 expression is increased in malignant cells and this may relate to is 
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putative role as a proliferative factor in CaP (58). The 6 trans-membrane protein of 
prostate 2 (STAMP2), also known as STEAP (six trans-membrane epithelial 
antigen of prostate) family member 4 (STEAP4)), is an androgen regulated 
metalloreductase that may also contribute to prostate cancer progression. 
Interestingly, STAMP2 has been implicated in adipocyte differentiation, 
inflammation and nutritional responses. The expression of STAMP2 is up-regulated 
early in many, but not all CaP tumors (59).  
Cell cycle related genes 
The cell cycle is a tightly regulated process leading to the duplication and division of 
a cell (60). Progression throughout the cycle is controlled by binding of specific 
cyclins to cyclin-dependent kinases (CDK). In the G0-phase, which is a resting 
phase, progression is mainly regulated by the gatekeeper, the retinoblastoma tumor 
suppressor protein (RB), which assembles repressor complexes on promoters of 
genes needed for progressing. The next phase, G1-phase, is when mitogenic 
stimuli have overcome RB repression and the cell size increases. Here different 
cyclin D’s are produced, which activate CDK4 and CDK6, which in turn 
phosphorylate and initiate the inactivation of RB. Further phosphorylation and 
complete inactivation of RB is mediated by CDK2. The CDK inhibitor 1A 
(p21Waf1/Cip1) is a negative regulator of the cell cycle and its expression is mostly 
related to increasing levels with progressing CaP (61, 62). p21Waf1/Cip1 is associated 
with the checkpoint in the G1-phase, where it inhibits CDK2. Cyclin A and E are 
responsible for the activation of CDK2 and they will also initiate the S-phase, where 
the DNA is replicated. In the following phase, the G2-phase, cell growth will 
continue and the progression is controlled by the levels of CDK1 (in humans named 
CDC2) with cyclin A and B complexes until the final phase, the M-phase (mitosis), 
where the cell divides. The cell cycle machinery controlled by cyclin-CDK 
complexes is further counterbalanced by mechanisms during cellular insults. The 
CDK inhibitor 1B (p27Kip1) is associated with several cell cycle checkpoints, by 
acting both on CDK2 and CDK1 (63, 64). p27Kip1 acts as a tumor suppressor and its 
expression is decreased in CaP. The phosphatase and tensin homologue (PTEN) is 
not directly related to the cell cycle, but acts as a major suppressor of protein 
kinase B (PKB, also known as Akt) signaling, which is a major pathway of growth 
receptor signaling. PKB activation is mediated by phosphatidylinositol 3-kinases 
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(PI3K), whereas PKB inhibition is mediated by PTEN (65). Its gene expression is 
commonly absent or reduced in approximately 60-80% of CaP cases, resulting in a 
constitutive activation of PKB by the PI3K pathway (66, 67). PKB is connected to 
p27Kip1 through AFX-like Forkhead transcription factors and PKB activation will 
result in reduced p27Kip1 levels (68). Tumor protein 53 (p53), is a tumor suppressor 
protein, also known as the genome watchman. It is associated with genome 
damage and the checkpoint in G1-phase before DNA replication. Its expression is 
also associated to p21Waf1/Cip1 and p53 expression is increased in later stage CaP 
(61, 69).  
Proliferative and apoptotic related genes 
Cellular proliferation, pro- and anti-apoptotic mechanisms are common in all 
cancers, also in CaP. Several molecular changes have been reported. The nuclear 
antigen Ki67 is associated with proliferating cells and its expression is noticeably 
induced in a few percent of epithelial cells in early CaP and its expression increases 
with CaP progression (70). Both the anti-apoptotic B-cell CLL/lymphoma 2 (BCL-2) 
and the pro-apoptotic B-cell CLL/lymphoma 2-associated X protein (BAX) protein 
expression levels are reported to be increased in CaP (71). The BCL-2 subfamily 
has several important functions in the regulation of apoptosis, including controlling 
the release of cytochrome c from the mitochondria, which in turn will activate the 
caspases, which will carry out the proteolysis during the demolition part of 
apoptosis (72). 
Neuroendocrine related genes 
The human prostate is composed of a glandular compartment with luminal and 
basal epithelial and scattered occasional neuroendocrine (NE) cells. There is also a 
stromal compartment composed mainly of stromal cells and to a lesser degree of 
endothelial cells, lymphocytes, fibroblasts and smooth muscle cells. The role of NE 
cells is still unknown, but it is proposed that they may have a paracrine function, 
supporting the growth, secretion and differentiation of the glandular epithelial cells 
(73). NE cells may be identified by the expression of chromogranin A (CgA) and 
neuron-specific enolase (NSE). Increased numbers of NE cells is associated with 
late stage CaP, especially CRPC. Also, in rare cases CaP may first appear as an 
aggressive small cell carcinoma expressing NE antigens (74).  
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1.4 GENISTEIN 
1.4.1 HISTORY OF THE SOY BEAN AND ITS USE  
The soy bean plant is one of the oldest known crops to mankind and may have 
been domesticated already 9000 years ago (75). The exact origin of domestication 
is still unclear, although the archeological evidence indicates Northern China, Korea 
and Japan. These are also the areas in which the populations consume the highest 
amount of traditional soy bean products, such as soy sauce, tofu (soy cheese), 
miso (soy bean paste soup) and edamame (boiled young soy beans in their pods).  
The word soy is derived from the Japanese word for soy sauce “shoyu” and it 
originated from the Dutch and Portuguese trade with Japan during the 16th century. 
The Europeans adopted the taste of soy sauce and it spread quickly across the 
continent with similar names; soy, soija, soia, soja or soya. At the end of the 18th 
and beginning of the 19th century scientists were interested in the presence of 
proteins, and the soy bean was identified to be rich in proteins. In fact, soy bean 
plants give the highest protein yield of all known cultivated crops per area.  
The independence of nitrate fertilizers makes the soy plant suitable for 
growing in poor soil (76). Most of the soy bean production today is used for soy oil, 
which accounts for 50 % of all plant oils. A large proportion is also used in animal 
food. Nearly all U.S. and most of Brazils, which are the two biggest producers, soy 
plants have been genetically engineered to withstand pesticides. Therefore, soy 
has a rather bad reputation for ecological and environmental preservation. 
 
1.4.2 BACKGROUND  
Its name was derived when its glycoside form, genistin (5,7,4'-trihydroxyisoflavone-
7-glucoside) (Fig. 4), was isolated from the plant Genistu tinctorb (Dyer's Broom) in 
1899 (77). The reason for its isolation was to examine its usefulness as a textile 
dyer. Genistein, which is the aglycone form of genistin, was first synthesized in 
1928 (78). Genistein belongs to the flavonoids, which are polyphenol compounds in 
plants with a yellow color. It is further divided into the isoflavonoids and finally 
isoflavones, which in addition to genistein also consist of daidzein and glycitein. 
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Additionally, genistein may also be regarded as a phytoestrogen. The two principal 
classes of phytoestrogens are the isoflavonoids (including coumestans) and lignans 
(79). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Molecule characteristics. 
 
In 1931, genistin was shown to be present in soy beans (78). In fact, soy 
beans are the principal human source of genistin, the prevalent natural form, which 
requires the bacterial flora in the gut of the consumer or an external fermentation 
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process to metabolize it to genistein before absorption (80). In addition, later 
studies have shown the existence of two additional glycoside conjugates consisting 
of 6”-O-malonyl-b-glucoside and 6”-O-acetyl-b-glucoside, although their existence 
may depend upon food processing conditions (81). Small amounts of genistein may 
be found in other plants (82). Table 1 shows the content of genistein in different soy 
based products.  
 
 
 
 
 
 
 
 
Table 1. Content of genistein 
 
The metabolic processes of absorbed genistein are elusive. One of the first 
findings was that genistein-glucoronide was detected when genistein was incubated 
with rabbit liver microsomal fractions and UDP-glucoronic acid (83). A more 
complex picture has later emerged. For the xenobiotic phase II metabolism, 
genistein is conjugated in the intestine and the liver during or after absorption by 
uridine 5'-diphospho (UDP)-glucuronosyltransferase and -sulfotransferases into 
glucuronides and sulfates (84). As shown in figure 4, two conjugating sites on the 
genistein molecule localized at positions 4’ and 7 have been suggested and a total 
of nine different forms may exist after absorption (85, 86). They include the 
unconjugated genistein and the eight metabolites; 4’ or 7 mono- and disulfates, and 
mono-, di- and sulfate-glucoronides. Most genistein is conjugated after absorption 
and unconjugated genistein represents only a few percent of total plasma genistein 
Soy oil 
Soy sauce 
Soy-based infant formula 
Soy milk 
Tofu 
Miso soup 
Roosted soy beans 
0 
1 
2 
6 
20 
25 
65 
mg/100 g 
Source: USDA-Iowa State University Database on the Isoflavone Content of Foods - 1999
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(84). In addition, there is also a phase I metabolism of genistein. In vitro studies 
have revealed involvement of cytochrome P450 superfamily (CYP) enzymes 
CYP1A2 and 2D6 generating hydroxyl metabolites, including orobol (87). However, 
the extent of phase I metabolism of genistein has been indicated to be much less 
than the phase II metabolism (88). 
Genistein and its metabolites are quite rapidly cleared from the body mainly 
by urine and partly by bile excretion (89, 90). The half-life of genistein in humans 
after oral administration is approximately 8 hours (91). Finally, there are major 
differences in genistein metabolism and conjugation both within and between 
species (92, 93). All these factors contribute to make exploring the metabolic 
processes of genistein difficult.  
 
1.4.3 CELLULAR AND MOLECULAR EFFECTS 
The cellular and molecular properties of genistein are several, diverse and not 
always coherent. Some of the properties are associated with high or very high 
concentrations of genistein (> 10 μM), whereas others can be seen at physiological 
relevant plasma levels in high consumers of soy products (0.5 – 5 μM). In addition, 
some of the effects have been reported as biphasic with stimulation at nanomolar 
and inhibition at micromolar concentrations. Several studies have used different 
mixes of soy extracts, containing variable amounts of genistein. The effects 
described in the present manuscript will focus on genistein alone. Undoubtedly, 
genistein is very pluripotent and the sheer scale of effects reported makes it 
impossible to discuss every finding. The division of effects made here does not 
represent any exclusivity and some of the effects may fit in several places. For 
example, genistein’s inhibiting effects on proliferation can be described by hormonal 
effects of androgens, by DNA modulation of DNA Topoisomerase II, by modulating 
cell cycle regulation or apoptosis, by effects on intracellular signaling pathways or 
even effects by its tyrosine kinase inhibiting properties on growth receptors. 
 In plants, genistein is a chemical attractant for the nitrogen fixating bacteria 
of the Bradyrhizobium genus, activating so called nod genes needed for the 
symbiotic relation (94). It also acts as a selective antibiotic, inhibiting growth of 
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some bacteria such as Staphylococcus aureus and Bacillus anthracis (95, 96). In 
addition, its estrogenic properties may act as part of a fertility modulation defense 
against herbivores (97). 
 
HORMONAL EFFECTS  
Estrogen 
Genistein is a phytoestrogen, meaning that it is an estrogenic compound found in 
plants. Its polyphenol structure has several characteristics similar to 17-estradiol 
(Fig 4). However, its estrogenic activity in vitro differs by having only 4 % of 17-
estradiol binding affinity for Estrogen Receptor  (ER) and 87 % for Estrogen 
Receptor  (ER), while not having any marked antagonistic activity similar to 
tamoxifen (98). In CaP, ER is associated with a protective role against abnormal 
proliferation of prostate epithelial cells by direct or indirect inhibition of ER (99). 
The difference between receptor specificity is also suspected to mediate positive 
health effects such as increasing bone mineral density and in women reduction of 
menopause associated hot flushes, without negative effects such as affecting 
endometrial thickness (100-102).  
Androgen 
Several reports indicate that genistein modulates the activity of wild-type AR by 
transactivating it and inducing a biphasic effect wherein nanomolar concentrations 
stimulates and micromolar concentrations depress its activity (103, 104). However, 
a well-known AR point mutation (T877A), frequently present in CaP and present in 
the CaP cell line LNCaP, changes the receptor ligand binding affinity and 
transactivation activity of AR to estrogen in addition to androgen (103, 105). 
Additionally, genistein depresses steroid synthesis and metabolism by inhibiting 
17-hydroxysteroid dehydrogenase and 5α-reductase (106, 107).  
Insulin 
Genistein is able to enhance the insulin secretion in insulin-secreting cell lines at 
nanomolar concentrations, independent of ER and inhibition of tyrosine kinase, by 
increased cyclic adenosine monophosphate (cAMP) and activated protein kinase A 
(PKA) (108). Increased insulin- and insulin growth factor (IGF) levels have been 
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associated with CaP and will act through the insulin receptor or IGF receptor (IGFR) 
on cells by sending a tyrosine kinase dependent mitogenic signal through PI3K to 
PKB (109). However, late results from clinical studies have challenged the idea that 
IGFR inhibition reduces CaP (110, 111). 
Thyroid 
Starting at low micromolar concentrations, genistein inhibited thyroid peroxidase 
(TPO) activity in rats up to 80 %, without affecting serum levels of thyroid 
stimulating hormone (TSH), triiodothyronine (T3) or thyroxine (T4), suggesting that 
the remaining TPO activity is sufficient for retaining TSH production or a separate 
mechanism (112) 
 
ANTI-OXIDANT 
Reactive oxygen species (ROS) and oxidation of vital proteins and DNA are 
suspected to be important factors in carcinogenesis (113). Genistein has been 
shown to inhibit the formation of hydrogen peroxide (H2O2), 8-Oxo-2'-
deoxyguanosine (8-oxo-dG) and malondialdehyde in skin of hairless mice exposed 
to ultraviolet B (UVB) radiation, either through indirect inhibition of neutrophil 
recruitment or direct quenching of ROS (114).  
 
TYROSINE KINASES 
Tyrosine kinases are involved in multiple cellular pathways and regulate the 
signaling activity of several cell growth receptors, such as epidermal growth factor 
receptor (EGFR), IGFR and fibroblast growth factor receptor (FGFR), which are of 
major interest in present-day cancer research and treatment (115). Genistein is a 
general inhibitor of tyrosine kinases and in vitro dose-dependently inhibits EGFR 
activity even at low micromolar concentrations, although complete inhibition 
required more than 100 μM (116). This finding has been disputed and it is on the 
other hand proposed that it is the EGFR protein level that is reduced by genistein 
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(117). However, genistein inhibits the activity of multiple tyrosine kinase regulated 
receptors (118).  
  
DNA MODULATION 
DNA topoisomerase II 
DNA topoisomerase II is an enzyme which unwinds and rewinds the DNA by 
breaking and re-ligating DNA during replication and transcription, so that the DNA 
becomes available for DNA polymerase (119). Topoisomerase II poisons are well 
established anti-cancer treatments, e.g. Doxorubicin. Genistein inhibits DNA 
topoisomerase II activity and induces single strand breaks at low micromolar 
concentrations and double strand breaks at high micromolar concentrations, 
possibly by competing for an Adenosine-5'-triphosphate (ATP) site (120). It has 
been suggested that the cytotoxic effects seen by genistein at very high micromolar 
concentrations are due to inhibition of DNA topoisomerase II activity (121). 
Telomerases 
The ends of the linear DNA in eukaryotic cells get shorter with each replication, 
resulting in genetic instability and senescence, which is prevented by telomerases 
adding a short repetitive DNA sequence (122). For immortality, cancer cells 
therefore have strong telomerase activity. Genistein at 30 μM inhibited telomerase 
activity in prostate cancer cell lines LNCaP and DU-145 (123). However, a more 
recent finding indicates that genistein induces a biphasic effect with increased 
telomerase activity in LNCaP, PC-3 and prostatic intraepithelial neoplasia (PIN) of 
the transgenic adenocarcinoma of the mouse prostate (TRAMP) at concentrations 
less than 1 μM, whereas a concentration at 50 μM depressed telomerase activity 
(124). The effect was coupled to the transcription factor Signal Transducer and 
Activator of Transcription 3 (STAT3), mediating the effects of interleukin 6 (IL-6) and 
c-Src, a tyrosine kinase. 
Epigenetics  
The regulation of genes above the level of DNA sequence which is propagating, 
self-sustainable and gives a transcriptional effect is called epigenetics (125). 
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Examples are the different phenotypes arising from the fertilized egg or stem cells. 
Modulators of epigenetics include microRNA (miRNA), DNA methylation and 
histone modifications. Starting at low micromolar concentrations, genistein reversed 
hypermethylation and reactivated the mRNA expression of retinoic acid receptor  
(RAR), tumor suppressor B-cell translocation gene 3 (BTG3) and other silenced 
genes in human cancer cells by inhibiting DNA methyltransferase and modulating 
histone deacetylase activities (126, 127). High micromolar concentrations have also 
been shown to induce the tumor suppressors aplasia Ras homolog member 1 
(ARH1) and phosphatase and tensin homolog (PTEN) in human CaP cells by 
epigenetic mechanisms (128, 129) 
 
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARS)  
The PPARs major forms, PPAR, PPAR and PPAR, are a group of receptors 
within the nuclear receptor family of ligand-activated transcription factors, involved 
in inflammation, lipid and carbohydrate metabolism (130). Genistein has been 
shown to transactivate PPAR at 10 μM and PPAR at 5 μM (131, 132). This may 
partly account for genisteins ability at physiological levels to inhibit lipogenesis and 
at high concentrations to enhance lipolysis in cell studies and lowering serum lipids 
in humans (133, 134).  
 
INTEGRINS, MATRIX METALLOPROTEINASES (MMPS) AND ANGIOGENESIS 
The integrins attach the cell to the extracellular matrix (ECM) or other cells and the 
MMPs is a family of proteins capable of degrading proteins in the ECM. Modulation 
of both families in a complex manner is necessary for cell adhesion, angiogenesis, 
tumor growth, invasion and metastasis (135, 136). Genistein at physiological levels 
has in vivo and in vitro been shown to increase cellular adhesion and dose-
dependently inhibit the expression of MMP-2 starting at a dose as low as 0.1 μM. 
This may account for reports that genistein inhibits the formation of metastasis in 
mice (137-139). Also, genistein inhibition of angiogenesis may be related to 
integrins and MMPs, although genistein also has a direct effect on endothelial cell 
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proliferation and expression of several other angiogenic factors at physiological 
levels (140, 141).  
 
MAJOR INTRACELLULAR PATHWAYS 
Akt/Protein Kinase B (PKB) 
The PKB signaling pathway is important for cell growth, differentiation and 
apoptosis by interlinking cell surface receptors with cell cycle regulators, such as 
p27Kip1, and transcription factors such as nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-B) (142). Genistein at 30 μM inhibited the activation 
(phosphorylation) of PKB, the transactivation of NF-B and NF-B DNA binding 
activity in the prostate cancer cell line PC-3 (143). Additionally, genistein at 50 μM 
induced the expression of PTEN, which expression was methylated and silenced in 
LNCaP and PC-3 cells (129). 
Mitogen Activated Protein Kinases (MAPKs) 
The MAPKs consist of a core of 3 sequential levels of serine/threonine-specific 
protein kinases where a MAPK3 activates a MAPK2 by phosphorylation, which in 
turn activates a MAPK, consisting of the 3 major conventional MAPKs; extracellular 
signal-regulated kinases (ERK) 1 and 2, c-Jun amino (N)-terminal kinases (JNK) 1-
3 and p38 isoforms -, in addition to several atypical MAPKs (144). The MAPK 
signaling cascades are activated in a complex manner by a wide variety of 
extracellular stimuli. Briefly, ERK has been implicated in growth responses, p38 in 
stress/inflammation and JNK in growth/apoptosis. Several reports show that 
genistein modulates all 3 major typical MAPKs at micromolar doses in human 
cancer cells, indicating that genistein have differential effects depending on cell line, 
although ERK and JNK are activated and p38 inhibited by genistein in CaP cells 
(137, 145, 146). 
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CELL VIABILITY  
Cell cycle 
Genistein has been shown to induce both G1 and G2/M cell cycle arrest, indicating 
that it has several effects on cyclin dependent kinases (CDKs) and/or cyclin 
dependent kinase inhibitors (CDKIs), which regulate the cell cycle (147, 148). 
Clearly, there are differences of reported induction on G1 or G2/M arrest not only 
between different cell lines, but also within the same cell line, e.g. LNCaP. The 
reason for this discrepancy is unclear, but technical differences in methodology or 
passage number of the cell lines may be suspected. Treatment of LNCaP cells with 
20-40 μM genistein have been shown to up-regulate the expression of the CDKIs 
p21Waf1/Cip1 and p27Kip1 and the “genome watchman” p53 (148, 149). 
Proliferation 
Genistein, starting at upper physiological concentrations, has been shown in vitro to 
dose-dependently inhibit the proliferation of human prostate-, breast-, liver-, 
leukemia-, lymphoma-, myeloma-, thyroid-, oral-, ovarian-, pancreas-, lung-, renal-, 
and gastrointestinal cancer cells (118, 150-160) 
Apoptosis 
Programmed cell death, apoptosis, is induced in several cell lines by genistein at 
very high concentrations (> 25 μM). It has been detected by multiple assays such 
as microscopy of nuclear bodies, tunnel assays, flow cytometry, caspases and poly 
(ADP-ribose) polymerase (PARP) cleavage (153, 161, 162). The B-cell lymphoma 2 
(Bcl-2) family consists of both pro-apoptopic proteins (Bax, Bad and Bak) and anti-
apoptopic proteins (Bcl-2 and Bcl-xL) and is considered to be the main regulators of 
apoptosis. The cell cycle associated genes p21Waf1/Cip1 and p53 may also be 
involved in the regulation of apoptosis (163). Genistein up-regulates Bax and down-
regulates Bcl-2 in prostate and breast cancer cells (147, 162, 164).  
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1.4.4 CLINICAL STUDIES  
The use of pure genistein in clinical studies has been rare until now, but is expected 
to increase with increasing availability. Pure genistein has been tested in phase II 
studies for menopausal symptoms and osteoporosis (100, 102). In CaP, there are 
no previous studies published which use pure genistein. However, there are several 
phase II studies using various mixes of soy based products and extracts. None of 
these were true RCT with placebo. All had prostate specific antigen (PSA) outcome 
as endpoint, although with various measurements. They may be sorted according 
to the stage of CaP. In early CaP, two studies with 76 and 29 subjects for 1 and 3 
months of intervention showed a stabilization or significant reduction of PSA 
respectively (165, 166). In early to late CaP, three studies with 39, 52 and 20 
subjects for 3 to 6 months of intervention showed reduction of PSA in early CaP 
and reduced increase of PSA in late CaP (167-169). In late CaP, one study with 20 
subjects for 12 months of intervention showed less increase of PSA (170). 
Generally it seems that the reduction in PSA by soy administration is greater in 
early compared to late CaP. 
 
1.4.5 TOXICITY 
Negative effects of genistein and soy isoflavones on female and male reproductive 
systems, breast and prostate cancer, risk of infant leukemia and thyroid function 
have been suggested based on cell and animal studies. These will be detailed in 
the following paragraphs. Some of these adverse effects have been attributed to 
genistein’s genotoxicity properties, which occur at high, non-physiological 
concentrations (171). Molecular suggested negative effects or toxicity by genistein 
have generally not been supported by clinical or epidemiological findings. No 
significant adverse effects were found in 248 Americans after 20-35 years, who 
were fed soy formula as infants compared to 563 who were fed cow-milk formula 
(172). However, a recent U.S. National Toxicology Program evaluation of genistein 
and soy isoflavones has concluded that “there is minimal concern for adverse 
effects on development in infants who consume soy infant formula”, i.e. graded as 2 
on a 5-level scale of concern (173). 
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Hormonal effects on men and female reproductive systems 
In men, increased exposure to environmental estrogens, such as soy foods have 
been suggested to be related to reduction in sperm quality (174). Likewise, in 
premenopausal women, estrogenic effects in the form of elongation of the 
menstrual cycle, decreased serum progesterone, SHBG, FSH and LH have been 
suggested (175). Several soy and genistein intervention studies have not detected 
any statistically significant alternations of menstrual cycle length or endometrium 
(176, 177). Neither are there any significant effects on the male sex hormones by 
soy intake (178). 
 
Breast cancer 
The estrogenic properties of genistein have been suggested to promote the 
development or progression of breast cancer in mouse models (179). However, this 
is not supported by neither the molecular effects as genistein preferably attaches to 
ER nor epidemiology as Asian high soy bean consuming countries have lower 
incidence of breast cancer (7). A recent phase II RCT with soy extracts on pre- and 
post-menopausal women in risk of breast cancer indicated a significantly higher 
proliferative index of breast gland epithelial cells in pre-menopausal, but not in 
postmenopausal women, compared with placebo (180). On the contrary, three 
recent large cohort studies have reported no adverse relation between breast 
cancer and soy intake (181-183). In fact, they suggest possible benefits for breast 
cancer survivors. 
 
Prostate cancer 
As opposed to the majority of chemopreventive reports of genistein treatment in 
CaP, there are mouse models showing increased metastasis caused by pure 
genistein. Genistein treatment in an orthotopic CaP model, in which the metastatic 
human CaP cell line PC-3 was implanted into the prostates of nude mice, resulted 
in a 2-fold increase in the size of para-aortic lymph nodes due to tumor infiltration 
(184). A similar experiment comparing pure genistein and a soy isoflavone mixture 
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composed of 43 % genistein, 21 % daidzein, 2 % glycitein and other components 
showed that the isoflavone mixture, as opposed to pure genistein, did not induce 
increased size of metastatic lymph nodes (185). The combination of daidzein and 
genistein has later been shown to have the same effect as the isoflavone mixture, 
indicating that daidzein is the mediator (186). Further, genistein treatment of a 
human metastatic CaP implanted in a Severe Combined Immunodeficiency (SCID) 
mouse model showed a highly significant increased frequency of metastases, 
proliferation and increased phosphorylation of EGFR (187). The implanted tumor 
had several passages with testosterone treatment in SCID mouse until it was highly 
metastatic. In another experiment in mice, genistein treatment of TRAMP with PIN 
induced a 70 % increase in lymph metastases (188). However, other mouse models 
indicate less tendency for metastases and the discrepancy of the results compared 
to those of other experiments may be related to different genetic profiles of mice, 
tumor or methodology (138, 139). Lakshman et al showed that genistein treatment 
of nude mice with orthotopic implanted PC3-M cells in prostate reduced lung 
metastases by 96% and that there were no difference in the weight of lymph node 
metastases (138). They also proposed that the anti-mobility effect by genistein 
might in fact increase attachment of orthotopic implanted CaP cells in nearby lymph 
nodes, whereas metastases are reduced at distal sites, i.e. a chemopreventive 
effect. In addition, Setchell et al. raised doubts about the use of rodent models for 
gaining insight into the effect of isoflavones in humans due to differences in 
metabolism of genistein (93). 
 
Infant leukemia 
Genotoxicity studies in vivo and in vitro have shown that genistein may increase 
breakage of genetic material, possibly by inhibiting DNA topoisomerase II (189). 
Children fed with soy based formula may reach the highest genistein 
concentrations, but may also be affected by maternal consumption during 
pregnancy. Genistein has been suggested to promote infant (less than 1 year) 
leukemia, a rare disease (190). One U.S. study using questionnaires linked 
maternal consumption of dietary DNA topoisomerase II inhibitors, including fruits, 
soy, green tea and coffee, to infant acute myelogenous leukemia (AML). However, 
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the author warned that the data were based on very few numbers (191). The rarity 
of the disease makes epidemiologic studies difficult. However, the incidence rate of 
leukemia in all age groups is less than half in Japan compared to U.S. (7).  
 
Thyroid disease 
Genistein dose dependently inhibits TPO in rats, and individuals with iodine or 
thyroid hormone deficiency may be more susceptible to the development of thyroid 
disease when including soy in their diet (112). However, no clinical adverse effects 
on thyroid function by genistein intervention have been found (192). 
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2.0 BACKGROUND AND AIMS OF THE STUDY  
The AR plays an essential role in growth of most CaP cells. Genistein is a 
pluripotent molecule that may regulate AR activity through multiple mechanisms. In 
the late 1990s, it was shown that genistein down-regulates the expression of PSA, 
an androgen regulated gene (ARG), in the human prostate cell line LNCaP (193). 
Later it was shown that genistein down-regulates both AR mRNA and protein 
expression in addition to inhibiting both promoter activity and binding to androgen 
response elements (AREs) in LNCaP cells (104, 194, 195). However, other reports 
indicated that genistein acted as an agonist in CaP cells and induced 
conformational changes in AR, increased its nuclear localization, activated the 
mutant AR T877A receptor and enhanced promoter activity (103, 196). At least at 
micromolar concentrations, genistein has been regarded as a general inhibitor of 
ARG, although the extent of inhibition is unknown. The transcription factor AP-1, 
consisting of c-jun and c-fos, may also act as a co-factor to AR and modulate its 
transcription. This may be a possible mechanism for genistein inhibiting ARG 
expression (197). 
Although genistein has shown a multitude of chemopreventive effects in cellular and 
molecular studies, no clinical studies on pure genistein alone in CaP has previously 
been performed. The reasons for this have been that pure genistein has not been 
easily commercially available in larger quantities and that several of the clinical 
studies which were performed on soy based products or isoflavones emphasized 
that the health benefits were from the isoflavones collectively, even though most 
cell- and molecular studies used genistein alone. Previous clinical studies, which all 
can be characterized as open-labeled or randomized phase II trials without placebo, 
indicate that soy isoflavones may lower the CaP surrogate end-point PSA in blood 
(164-170). 
 
Paper I 
The aims of the pre-clinical study were in LNCaP cells to investigate whether 
genistein modulates: 
1) the expression of well-known androgen regulated genes; PSA, AR, NKX3.1, 
KLK4 and STAMP2. 
2) the MAPKs end targets JNK and c-jun. 
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Paper II and III 
The aims of the RCT were to investigate in human patients having localized CaP: 
3) if genistein modulates PSA in blood and prostate tissue. 
4) if genistein modulates prostate pathology. 
5) if genistein modulates biomarkers associated with development and 
progression of CaP, including androgen-, cell cycle-, proliferation-, apoptosis- 
and neuroendocrine related genes.  
6) if genistein modulates blood lipids, sex- or thyroid hormones. 
7) if total genistein in plasma change upon administration. 
8) if the pure synthetic genistein intervention is safe in humans.  
 
Paper IV 
The aims of this study was to investigate the presence and compare the distribution 
of genistein aglycone and its main phase II conjugates in human plasma and 
prostate tissue compartments in patients with localized CaP. 
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3.0 SUMMARY OF PAPERS 
3.1 PAPER I 
Genistein differentially modulates androgen-responsive gene expression and 
activates JNK in LNCaP cells. 
 
The extent of down-regulation in PSA and AR by genistein has varied between 
publications. The purpose of this study was to examine if genistein modulates gene 
expression in five distinct ARGs and activates JNK and c-Jun in LNCaP cells. 
 
AR, PSA, KLK4, NKX3.1 and STAMP2 were examined at the messenger 
ribonucleic acid (mRNA) level with quantitative real-time polymerase chain reaction 
(qRT-PCR) and protein level with Western blotting in LNCaP cells. Total and 
phospho-JNK were examined with Western blotting whereas c-jun was examined 
with solid phase kinase assay with 32P-ATP by using the fusion protein gluthatione 
S transferase (GST) c-jun. 
 
We showed that whereas there are inhibitory effects of genistein on the ARG 
protein accumulation, the effect on mRNA levels did not always coincide with this, 
suggesting that there are different mechanisms through which genistein affects the 
AR signaling pathway. Further, genistein directly activated JNK signaling transiently 
at 3 hours, which was evident both in the phospho-JNK and the solid phase assay. 
 
Our conclusions were that genistein differentially modulates the ARG mRNA 
expression in LNCaP cells and inhibits ARG protein expression. Genistein activates 
the JNK pathway in LNCaP cells, which may in part explain the reduction of the 
ARG protein levels in response to genistein. 
 
 
 
 
 
 
 36
3.2 PAPER II  
Efficacy and safety of short-term genistein intervention in patients with 
localized prostate cancer prior to radical prostatectomy: a randomized, 
placebo-controlled, double-blind phase 2 clinical trial. 
 
There is no previous phase II RCT reported on genistein alone in CaP. The purpose 
of this study was to examine if genistein modulates the primary endpoints PSA, 
testosterone and biomarkers associated with development and progression of CaP. 
Secondary endpoints included safety, prostate pathology, genistein plasma 
concentration, blood lipids, sex- and thyroid hormones.  
 
Forty-seven patients were randomized to daily intervention by 30 mg genistein or 
placebo for 3 to 6 weeks prior to prostatectomy. Seven patients were non-compliant 
to the study protocol. 
 
Serum PSA decreased close to statistically significant level and the protein 
expression of PSA in prostate tissue was significantly higher in Gleason grade 4 
tumor compared to normal tissue in the genistein arm. Total cholesterol was 
significantly lower in the genistein arm. There were no effects on thyroid or sex 
hormones. Adverse events were few and mild.  
 
Our conclusions were that there may be a possible therapeutic effect by genistein in 
early CaP and that the anticancer effect by genistein suggested by our observations 
could explain the epidemiological data indicating a preventive effect of a diet rich in 
soy products. Synthetic genistein was safe to use. 
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3.3 PAPER III 
The effects of short term genistein intervention on prostate biomarker 
expression in patients with localized prostate cancer prior to radical 
prostatectomy. 
 
The purpose of this study was to examine if genistein modulates biomarkers 
associated with development and progression of CaP. 
 
Thirty-nine prostates from patients randomized to daily intervention by 30 mg 
genistein or placebo for 3 to 6 weeks were examined. Glandular cells were isolated 
by laser capture micro dissection and the mRNA level of androgen related 
biomarkers (AR, NKX3.1 and KLK4) and cell cycle related genes (p21, p27, p53) 
were analyzed with qRT-PCR. Immunohistochemistry of androgen-, cell cycle-, 
proliferative- (Ki67), apoptotic- (BCL-2 and BAX) and neuroendocrine related 
biomarkers (NSE and CgA) was performed using tissue microarrays containing 
normal and Gleason grade 3 and 4 tissue. 
 
We showed that genistein intervention significantly reduced the mRNA level of 
KLK4 in tumor cells and induced a non-significant reduction in androgen and cell 
cycle-related biomarkers, except for p27, whose expression in the nuclear 
compartment was increased. 
 
Our conclusion was that genistein intervention at nutritionally relevant levels in 
patients with early CaP modulated several biomarkers which may be related to 
cancer prediction and progression. 
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3.4 PAPER IV 
Disposition of synthetic genistein in humans induces genistein to genistein-
phase II metabolite ratio differences in plasma and prostate tissue. 
 
The purpose of this study was to investigate the presence and compare the 
distribution of genistein aglycone and its main phase II conjugates in human plasma 
and prostate tissue in patients with localized CaP. 
 
Seventeen paired samples containing plasma and prostate tissue from patients 
treated daily by 30 mg synthetic genistein orally for 3 to 6 weeks (average 34 days) 
were analyzed with liquid chromatography-electrospray ionization-tandem mass 
spectrometry (LC-ESI-MS/MS). 
 
We showed that the distribution of both genistein aglycone and its conjugates was 
significantly different between plasma and prostate tissue. Corroborating previous 
reports, there was very little unconjugated genistein in plasma. On the other hand, 
nearly half of the total content of genistein in prostate tissue was composed of the 
biological active aglycone. We also found a high content of genistein-sulfate in both 
compartments whereas genistein-glucoronide contents were low. 
 
The results indicate that oral administration of genistein alone induces high ratios of 
the aglycone form in prostate tissue. The distribution may differ compared to a mix 
of soy isoflavones, leading to more genistein-sulfates and less genistein-
glucoronides in both plasma and prostate tissue. 
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4.0 METHODS 
Important aspects of the methods used in our studies are presented in this section. 
It also contains some information not added in the original publications. More 
detailed information on methods is given in the original publications. 
 
4.1 PRE-CLINICAL STUDY 
4.1.1 CELLS AND TREATMENTS 
The androgen responsive human CaP lymph node metastatic cultured cell line 
LNCaP were used in all experiments and the passage numbers were between 10 
and 20. The passage number for LNCaP is important as the cells develop AR 
independence in later passages (198). The cells were hormonally starved by using 
charcoal treated (ChT) bovine serum both before and during treatments to avoid 
any confounding effects (199). In order to achieve hormonal starvation before 
treatment, the cells were grown for 48 h in RPMI with 2% ChT fetal calf serum 
(FCS), followed by 24 h in RPMI medium with 0.5% ChT FCS. Consistently, 2 μM, 
10 μM and 50 μM genistein were used in all treatments. 
 
4.1.2 METHODOLOGICAL ASPECTS 
The solid phase kinase assay used GST fusion proteins coupled to gluthatione 
agarose beads, which were incubated with treated whole cell extracts, resulting in a 
strong binding of JNK, if activated, to c-jun. After washing the beads extensively 
from excess proteins, addition of the radioactive isotope 32P-ATP resulted in the 
phosphorylation of two serines on c-jun and the dissociation of JNK from the 
complex (200). The radioactive phosphorylated c-jun was thereafter separated on 
gel according to size and detected on radioactive sensitive film. The qRT-PCR cycle 
threshold (CT)-values were adjusted towards the CT-values of the reference gene 
ATP-6. The PCR efficiency correction model by Pfaffl was used for all calculations 
(201).  
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4.2 CLINICAL RANDOMIZED TRIAL 
 
4.2.1 ACCRUAL  
Table 2 shows the accrual data. Patient recruitment is depicted in figure 1 in paper 
II. During the study period 217 LRPs were performed. Nearly all study patients were 
recruited at the OUU outpatient clinic. A few patients missed at the outpatient clinic 
or diagnosed in a private clinic were recruited after a personal meeting with the 
principal investigator. About one quarter of all patients treated by LRP during the 
study period was recruited into the study. Our exclusion criteria were quite stringent. 
Patients with place of residence more than 150 km from Oslo were excluded to 
secure adequate follow-up in case of the occurrence of adverse events during the 
intervention period. The next common cause for exclusion was patients on 
anticoagulative treatment, due to uncertain interaction between genistein and the 
anticoagulants. About 1/3 of the LRP patients not included in the study were 
missed. The efficiency of the study (number of patients included/total number of 
eligible patients) was close to 50 %. 
 
4.2.2 METHODOLOGICAL ASPECTS 
We expected that most patients included in the study would be treated surgically 
within 3 to 4 weeks, which was the current waiting time for LRP at study startup. 
The average days of intervention in both arms turned out to be 33 days. There were 
2 to 14 days (average 8 days) latency between recruiting and startup of the 
intervention, during which time base-line samples were analyzed, patients 
randomized and study drugs delivered. We expected that changes in the primary 
endpoints would be apparent within a few weeks of intervention and that further 
intervention for a few weeks was unlikely to have any major influence. The time of 
intervention was more likely to have an influence on the secondary endpoints of 
pathological analysis and the intervention time was stratified in respect to the 
respective endpoint. However, the numbers of patients were too low for statistical 
analysis.  
Instead of ATP-6, the qRT-PCR cycle threshold (CT)-values were adjusted towards 
the CT-values of the reference gene delta-aminolevulinate synthase 1 ALAS1 in this 
study. Additionally, (TATA-binding protein) TBP and glyceraldehyde-3-phosphate 
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dehydrogenase (GAPDH) were tested as housekeeping genes before deciding for 
ALAS1. The PCR efficiency correction model by Pfaffl was used for all calculations 
(201). 
 
 Number Percentage
Patients listed for LRP at OUU one week before surgery 
during 140507-040808. 
217 100,00
Patients recruited to Genistein study 54 24.9
Exclusion criteria, reasons:  
 Living in remote area 40 18.4
 Anti coagulative treatment 33 15.2
 Doctor/patient discretion 15 6.9
 Surgery within 3 weeks 9 4.2
 Hypothyreoid 4 1.8
 Liver or pancreas disease 2 0.9
 Intestinal disease 0 0
 Extreme dietary habits 0 0
 Hormonal therapy or chemotherapy 0 0
 Hormone dependent malignancies 0 0
 Allergy 0 0
 Subtotal 103 47.5
Missed, reasons:  
 Unknown 40 18.4
 Suspicion of advanced cancer 12 5.5
 Admitted through private clinic 8 3.7
 Admitted before study start-up 1 0.5
 Subtotal 61 28.1
Efficiency (Recruited/(Total-Exclusion)) 54/114 47.4
 
Table 2. Accrual report 
 
4.2.3 STATISTICS 
In the power analysis (paper II), we assumed a monthly PSA rise by 15–30 % in 
pre-intervention arms with CaP and a mean PSA level by 10 g/L, based on 
previous reports (167). However, the degree of monthly PSA rise (velocity) in 
localized CaP is disputed. Other authors have reported a yearly increase by 15 % in 
localized CaP and 30 % in advanced CaP (202). In our study the average PSA 
velocity in the placebo arm was 4.4 % over an average period of 33.9 days. We 
needed at least 17 patients in each arm to demonstrate a difference in PSA level by 
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2 g/L at a significance level of 0.050 and a power of 0.80, assuming equal 
standard deviation of 2 g/L in both arms. Having 23 patients in the genistein arm 
and 17 in the placebo arm this requirement was accomplished. In paper II, we 
tested differences between the two arms by 2 independent sample t-tests or Mann-
Whitney test, whereas differences in distributions of categorical variables between 
the two arms were tested by Fisher’s exact test. In paper III there were fewer 
samples due to losses during analysis and stratification. Therefore we tested 
differences between two related and independent samples by Fisher-Pitman 
permutation tests for paired and two-sample interval-scaled data. The p-values 
were based on 2000 simulations or permutations, which reduced the probability of 
false positive findings. The permutation tests do not require normality of data and 
are not dependent on the sample size. However, the study was limited by the small 
number of cases included and also by the relatively short time of intervention. Only 
10 patients in the genistein arm and 12 in the placebo arm could be included for the 
mRNA measurements. Thus, the results are prone to statistical errors of type I and 
II in the investigation of multiple parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43
5.0 DISCUSSION 
5.1 GENISTEIN MODULATION OF AP-1 MAY REGULATE ARG EXPRESSION 
Genistein is a pluripotent molecule with effects that may coincide with different 
pathways and in some respects also may be paradoxical, i.e. stimulative at 
nanomolar and inhibitory at micromolar concentrations. ARG expression is naturally 
regulated by or responsive to the AR at a significant degree, although it may also be 
regulated by other transcription factors. AP-1 is a transcription factor, composed of 
the MAPK end targets c-jun, activated by JNK, and c-fos, activated by ERK, that 
additionally may act as a co-repressor to AR by direct interaction between the DNA 
binding domains of AR and c-jun (197, 203, 204). Therefore, our finding in paper I 
that genistein transiently activates JNK in CaP cells is important in regard to AR 
function and ARG expression. Others have reported that among the MAPK end 
targets, JNK was not modulated by genistein, as opposed to p38 and ERK. Possibly 
this may explain the effects by genistein on growth and inflammation (137, 205). 
However, the reports are not unambiguous and there are several indications that 
JNK may be activated by genistein in some cell types (146, 206). It is therefore 
plausible to imagine a mechanistic signaling pathway for genistein. It may first affect 
tyrosine kinases to growth receptors, as a general tyrosine kinase inhibitor, above 
the MAPK chain. This in turn may modulate the complex signaling in the MAPK 
chain, resulting in a transient activation of JNK and c-jun because of genistein’s 
rapid half-life and conversion to metabolites. Finally it may repress AR function and 
ARG expression through AP-1. Alternative hypotheses may be proposed. For 
example, LNCaP cells containing the T877A mutation in AR, which makes them 
sensitive to estrogens, may also make genistein an antagonistic ligand and induce 
a direct inhibitory effect on transactivation and transcription (207, 208). Additionally, 
the superfamily of nuclear receptors and other transcription factors in many cases 
share the same co-factors, which may result in more efficient recruitment of co-
factors needed by AR during genistein stimulation (209, 210). Genistein may also 
modulate AR directly by any of the several hundred other co-factors (see NURSA at 
http://www.nursa.org/). In paper I we showed that genistein did not inhibit mRNA 
levels in all ARGs, which may indicate a non-AR dependent mechanism. The 
complexity of AR function and the pluripotency of genistein make it difficult to 
demonstrate a certain superior credibility of one hypothesis compared to another. 
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Most probably, genistein modulation of ARG expression depends on several 
effects.  
 
5.2 GENISTEIN MAY BE A CHEMOPREVENTIVE AGENT IN EARLY CAP 
In paper II we investigated the percentage change in serum PSA in patients with 
localized CaP. There was a close to statistically significant difference between the 
two study arms, with a reduction by 7.8 % in the genistein arm and an increase by 
4.4 % in the placebo arm. In direct values, there was an 11.3 % decline in the 
genistein arm (1 μg/L / 8.9 μg/L) and a 1.2 % increase in the placebo arm (0.1 μg/L 
/ 8.2 μg/L). Interestingly, this shows that the reduction in serum PSA levels reported 
by clinical studies using soy bean products can be caused by genistein alone (211). 
It also indicates, although does not prove, that genistein may have a measurable 
clinical effect as a chemopreventive agent. 
 We showed that there was a significant difference between the expression 
levels of PSA in prostate tissue of Gleason grade 4 in the two intervention arms. 
There was reduced expression in the placebo and normal expression in the 
genistein arm. However, the number of patients having Gleason grade 4 tumors 
was few, and the significance of this finding needs further research.  
 There was no association between the number of intervention days and the 
extent of decline in serum PSA in the genistein arm. This may be due to a low 
number of patients and the relatively short length of intervention time. Possibly an 
increase in these elements would have detected a more pronounced effect by 
Genistein on the level of PSA.  
 In paper III we observed several interesting findings indicating possible 
chemopreventive properties of genistein. Firstly, there was a general reduction in 
the genistein arm of the androgen related biomarkers. This corroborates our in vitro 
findings in the LNCaP cell line (paper I). It also indicates that the administration of 
genistein in humans, at much lower concentrations than in vitro studies, but of 
longer duration, may have similar effects. Interestingly, in our LNCaP study (paper 
I) we showed that genistein did not reduce KLK4 mRNA, which on the contrary 
seemed to increase. In our in vivo studies however, (paper II), KLK4 mRNA was the 
only androgen related gene whose expression was significantly reduced. This may 
indicate cell specific effects by genistein, although the protein expression in both 
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studies was reduced. Secondly, the cell cycle related gene expression in general 
was reduced, except for p27Kip1, whose protein expression in the nuclear 
compartment was increased compared to the placebo arm. We expected that 
genistein as a chemopreventive agent would increase the expression of the cell 
cycle related genes, which would corroborate previous in vitro based reports (148, 
149). The increased expression of p27Kip1 in the nuclear compartment in the 
genistein arm and its reduction in the placebo arm may however support anticancer 
effects by genistein. Loss of PTEN function and/or constitutive activation of PKB by 
the PI3K pathway, commonly found in CaP, will reduce the expression of p27Kip1 
(67, 68). Genistein inhibits PKB constitutive activation by reestablishing PTEN 
expression by its epigenetic modulation. Our result may therefore indicate the 
mechanism for its cycle arrest and proliferation inhibition of tumor cells (129, 143, 
147). The longer duration of intervention in our clinical study compared to the short 
duration in cell studies, may also explain why the other cell cycle related markers 
were normalized.  
 To summarize, we showed that genistein intervention had measurable 
effects on biomarkers in both blood and prostate tissue in patients with localized 
CaP. As of today the most reliable biomarker in CaP is of course the surrogate end-
point serum PSA. However, the other androgen related biomarkers may also be of 
importance as biomarkers of prediction and progression of CaP. We also showed 
that genistein in vivo may modulate cell cycle related biomarkers, explaining 
inhibitory effects of cell cycle and proliferation.  
 
5.3 GENISTEIN HAS NO EFFECTS ON SEX HORMONES IN THE CIRCULATION 
One could have suspected genistein to modulate PSA and androgen related genes 
by modulating testosterone levels. This is supported by cell- and molecular studies 
which have shown that genistein both inhibits 17-hydroxysteroid dehydrogenase 
and 5α-reductase (106, 107). However, 17-hydroxysteroid dehydrogenase is 
simply one pathway for metabolizing androstenione to testosterone, whereas 
androstenediol may be metabolized to testosterone by 3-beta-hydroxysteroid 
dehydrogenase (3-HSD) (212). On the other hand, 5α-reductase metabolizes 
testosterone to the much more potent dihydrotestosterone. We showed that 
genistein does not modulate testosterone levels in blood. We also investigated 
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luteinizing hormone (LH) and sex hormone-binding globulin (SHBG); the other sex 
hormones associated clinical biomarkers, without finding any significant effect by 
genistein intervention. 
 
5.4 GENISTEIN HAS NO EFFECTS ON THYROID HORMONES IN THE CIRCULATION 
Genistein has been reported to inhibit TPO in several species, including humans. In 
vivo effects by genistein on T3 and T4 in rats and cats have been reported. The 
reports however are not unambiguous (112, 213, 214). Several human studies with 
soy or genistein have reported no significant effects on thyroid function, 
corroborating our results (192, 215, 216). The discrepancies between species may 
be explained by different metabolic pathways and effects (93). 
 
5.5 GENISTEIN LOWERS SERUM CHOLESTEROL 
Soy has previously been shown to be strongly associated with lowering of serum 
cholesterol levels. It is not clear however whether this effect can be attributed to soy 
protein alone or isoflavones (134). Genistein may affect lipid metabolism through 
the PPAR or inhibition of the gene expression of hormone sensitive lipase or 
lipoprotein lipase (133, 217). No previous human clinical trials with genistein alone 
have reported a full lipid analysis, although HDL cholesterol was reported to be non-
significantly increased in one study (218). In our study, serum total cholesterol was 
significantly lowered by genistein alone, although the average percentage reduction 
was only 4 %. The reduction in LDL- and HDL-cholesterol was non-significant. S-
lipase and S-triglycerides were not affected. 
 
5.6 GENISTEIN PHASE II METABOLISM DIFFERS IN BLOOD AND PROSTATE 
TISSUE  
In paper IV we detected two interesting findings. Firstly, the ratio of genistein 
aglycone was significantly higher in prostate tissue compared to plasma. Secondly, 
genistein-sulfates were the dominating form in both compartments. The conjugated 
forms of genistein are not considered as bioactive as the aglycone form (219). 
Genistein-sulfates may be a resource for the aglycone form by the action of specific 
sulfatases, whereas the glucoronide form cannot be reversed (220). The expression 
of sulfatases in some cancer cells, including the CaP line LNCaP, may be increased 
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compared to normal cells (221). Our results differ from other studies which show the 
glucoronide form to be the dominating in plasma, tissue and urine (85, 86, 222). 
The reason for this discrepancy is unclear. However, there are no previous reports 
comparing the amount of genistein aglycone and all major conjugates in both blood 
and prostate tissue compartments. We are also the first to test genistein aglycone 
alone and not several isoflavones, which may have effects on conjugation and 
bioavailability by saturation of transferase enzymes. A recent small study on 
genistein and genistin supports our finding that sulfate conjugates are increased 
and glucoronide conjugates are decreased in plasma when consuming pure 
genistein (223).   
 
5.7 GENISTEIN IS SAFE TO USE IN CAP PATIENTS 
We defined an adverse event (AE) as any untoward medical occurrence in a patient 
or clinical investigation subject which was temporally related to protocol procedures, 
including the administration of a pharmaceutical product at any dose. It was not 
required for the occurrence to have a causal relationship to the treatment. The AEs 
were graded into a five-level scale including, mild (1), moderate (2), severe (3), life-
threatening (4) and fatal (5). AEs grade 1-2 were considered as non-serious and 
AEs grades 3-5 as serious.  
 Only a few grade 1 AEs were reported, mostly of gastrointestinal origin. They 
were equally distributed in both intervention arms. In the genistein arm one patient 
experienced increased tiredness during the study period and one had heart 
palpitations. He had had this condition for several years and investigations did not 
reveal pathology. The intervention was completed as planned in both cases.  
 In the genistein arm we noted transient biochemical AEs in two patients. One 
patient had an increase in S-lipase, without other effects on blood lipids. Another 
patient had a slight transient increase in S-bilirubin without change in other liver 
parameters. The biochemistry were normalized in both patients. In summary, our 
results show that 30 mg genistein daily is well tolerated without yielding any marked 
AEs. This corroborates the results of previous studies on soy based products.  
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6.0 CONCLUSIONS  
1. Genistein inhibits the protein expression of the following ARGs: PSA, KLK4, 
NKX3.1 and STAMP2 in LNCaP cells. 
2. The MAPK end targets JNK and c-jun are phosphorylated by genistein, 
which may activate the AR cofactor AP-1 and inhibit AR in LNCaP cells. 
3. Intervention with a daily dosage of genistein, easily acquired by food, for 3 to 
6 weeks reduces serum PSA close to significant level in patients with 
localized CaP. 
4. In patients with localized CaP, genistein intervention yields a PSA protein 
expression in Gleason grade 4 prostate glands at the same level as normal 
prostate tissue, whereas the PSA expression in non-treated tissue is weaker 
with increasing Gleason grade.  
5. Androgen related gene expression of AR, KLK4 and NKX3.1 in prostate 
glands of patients with localized CaP is generally reduced by genistein 
intervention.  
6. Cell cycle related gene expression of p21Waf1/Cip1, p27Kip1 and p53 in prostate 
glands of patients with localized CaP is generally reduced by genistein 
intervention, whereas the protein level of nuclear p27Kip1 is increased.  
7. Genistein does not modulate blood sex or thyroid hormones in patients with 
localized CaP. 
8. Genistein significantly lowers blood total cholesterol in patients with localized 
CaP. 
9. Genistein is differently metabolized in prostate tissue and plasma in patients 
with localized CaP. 
10. Genistein is safe to use in patients with localized CaP.  
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7.0 FUTURE PERSPECTIVES 
Genistein has been investigated as a chemopreventive agent for CaP during the 
last 20 years. However, commercially available pure genistein was not introduced 
until about 2005. It is still not marketed in European countries due to EU regulations 
labeling it as a novel substance. However, it is available in the U.S. Soy has been 
consumed for several thousands of years in some Asian countries, and it is clear 
that these countries have a considerable lower rate of both breast and prostate 
cancer. On the other hand, there are occasional warnings that genistein may have 
an opposite effect. Often these warnings are based on single research reports on 
cell or animal studies, performed under special circumstances with high non-
physiological levels of genistein. In addition, there are differences in effects of 
genistein between species, which may be attributed to different metabolism, making 
animal studies unsuitable for deducing effects in humans.  
 
The author believes, based on research reports declaring it safe and beneficial for 
health, that soy consumption and nutraceutical additives of genistein are likely to 
increase in Western countries in the future. The intake of pure genistein will 
probably reduce the risk of allergy compared to consumption of soy. Also the 
administration of pure genistein would be easier, considering the rapid clearance. 
Genistein and soy isoflavones already belong to the most investigated food derived 
molecules. Soy production has several positive environmental effects in general. 
Soy plants, cultivated in the appropriate way, are beneficial to the soil, rivers and 
lakes, reducing the use of artificial fertilizer of nitrates. Consumption of red meat is 
coupled to several cancers including CaP. 
 
The final answer as to whether genistein is a chemopreventive agent in CaP cannot 
be resolved until a large phase III-IV RCT is performed over a long period of time. 
Unfortunately, this will probably not be realized during the next 5-10 years. 
Implementation of such a study will be very costly, and it will render necessary the 
participation by several countries. The disappointing results in the SELECT study 
may also be discouraging. However, genistein is one of the top candidates of 
natural chemopreventive agents in CaP. Its effects are clinically measurable in 
patients having localized CaP already after one month of administration. The effects 
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probably will be more pronounced after a longer treatment period and twice daily 
orally administration. Men having low grade CaP and treated by active surveillance 
will be an especially interesting group to investigate the possible efficacy of 
genistein. A phase II-III RCT at this stage of the disease may find that genistein 
reduces the progression of CaP and therefore the need for surgery or radiation. A 
major problem in such a study however will be patient compliance, due to the 
prognostic uncertainty felt by the individual patient. Another obstacle may be soy 
danger reports in the popular press or internet. The author regards it unlikely that 
genistein alone, at dosages that may be acquired by food, will have any effect on 
high grade CaP considered for surgery or radiation. Finally, further exploration on 
genistein effects in CaP, both in vivo an in vitro, may lead to novel understandings 
and treatment modalities of the disease. 
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Abstract
Nutritionally relevant levels of genistein, the predominant isoﬂavone in soyabean associated with lower risk of prostate cancer (PCa),
may modulate the expression of prostate tissue biomarkers associated with cancer prediction and progression. A phase 2 placebo-
controlled, randomised, double-blind clinical trial was conducted in forty-seven Norwegian patients before prostatectomy. Intervention
was 30mg genistein or placebo capsules daily for 3–6 weeks. Luminal cells from malignant and benign glands were isolated
with laser capture microdissection and the mRNA levels of androgen-related biomarkers (androgen receptor, NK3 homeobox 1,
kallikrein-related peptide 4 (KLK4)) and cell cycle-related genes ( p21 Waf1/Cip1, p27 Kip1, p53) were analysed with real-time semiquan-
titative PCR. Immunohistochemistry of androgen-, cell cycle-, proliferative- (Ki67 nuclear antigen), apoptotic- (B-cell CLL/lymphoma 2
(BCL-2) and BCL-2-associated X protein) and neuroendocrine differentiation-related biomarkers (neuron-speciﬁc enolase and cyto-
plasmic chromogranin A) was performed using tissue microarrays containing normal, Gleason grade 3 and grade 4 prostate tissues.
There were no signiﬁcant effects by genistein intervention on proliferation-, cell cycle-, apoptosis- or neuroendocrine biomarkers.
Genistein intervention, however, signiﬁcantly reduced the mRNA level of KLK4 in tumour cells (P¼0·033) and there was a non-
signiﬁcant reduction in androgen and cell cycle-related biomarkers, except for p27Kip1, whose expression in the nuclear compartment
was increased. Genistein intervention modulated the expression of several biomarkers which may be related to PCa prediction
and progression. The present study supports genistein as a chemopreventive agent in PCa. Further investigation is warranted in
larger and longer-duration studies.
Key words: Biomarkers: Genistein: Immunohistochemistry: PCR: Prostate cancer
Although not an ideal biomarker, serum prostate speciﬁc
antigen is the only predictive and prognostic prostate cancer
(PCa) biomarker widely used in clinical practice. Several pro-
teins have been proposed as candidate biomarkers exhibiting
all or some of these predictive or prognostic properties(1–3).
Among these are androgen-, cell cycle-, proliferation-, apop-
tosis- and neuroendocrine differentiation-related biomarkers.
The soya isoﬂavone, genistein, is a promising chemo-
preventive agent in PCa based on molecular, epidemiological
and clinical studies(4,5). We have previously reported the
clinical endpoints of a phase 2 clinical randomised trial with
short-term genistein intervention in patients with localised
PCa. Genistein reduced the level of serum prostate speciﬁc
antigen without any effects on hormones(6). The purpose of
*Corresponding author: B. Lazarevic, fax þ47 22935944, email bato.lazarevic@medisin.uio.no
Abbreviations: AR, androgen receptor; BAX, B-cell CLL/lymphoma 2-associated X protein; BCL-2, B-cell CLL/lymphoma 2; CgA, cytoplasmic chromogranin A;
G3, Gleason grade 3; G4, Gleason grade 4; KLK4, kallikrein-related peptide 4; NKX3·1, NK3 homeobox 1; NSE, neuron-speciﬁc enolase; p21Waf1/Cip1, cyclin-
dependent kinase inhibitor 1A; p27Kip1, cyclin-dependent kinase inhibitor 1B; p53, tumour protein p53; PCa, prostate cancer.
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the present study was to investigate the modulation of
potential candidate PCa tissue biomarkers by genistein at a
dose that can be obtained from a diet rich in soya-based food.
Experimental methods
Patients and study design
A total of forty-seven patients with localised PCa scheduled to
be treated by radical prostatectomy were randomised during
April 2007–August 2008. Next, a total of forty-one prostates
were analysed and forty were considered as evaluable
according to the study protocol. However, one specimen only
contained enough tumour material for pathological analysis
and could therefore not be analysed for biomarkers. The study
was a single-centre, placebo-controlled, randomised and
double-blind phase 2 clinical trial with two treatment arms(6).
One arm was given 30mg synthetic genistein (geniVidaw(7))
daily and one arm received placebo. The intervention period
was 3–6 weeks (average 33d) before radical prostatectomy.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involving
human subjects/patients were approved by the Norwegian
Medicines Agency, the Regional Ethics Committee, the
Privacy Ombudsman and the Prostate Biobank at the Oslo
University Hospital, Aker. Written informed consent was
obtained fromall subjects/patients. The studyhasbeen registered
in the ClinicalTrials.gov registry (study identiﬁer: NCT00546039).
Tissue processing, laser capture microdissection and
RNA isolation
After surgery, the prostates were immediately transferred to the
pathology department and macro-dissected by a pathologist.
Fresh tissue cubes, approximately 0·5 cm3, were cut from
tumour and normal tissue and frozen at 2808C. Frozen 10mm
sections were stained with haematoxylin and eosin. At least
10 000 cells from histologically benign and cancer glands from
each patient were selected and captured using laser capture
microdissection (Leica LMD 6000; Leica Microsystems) and
frozen at 2808C(8).
Total RNA was isolated using the Arcturus PicoPure RNA
Isolation Kit (Molecular Devices) according to the manufac-
turer’s protocol. The concentration of RNA was determined
by measurements in the NanoDrop ND-1000 spectropho-
tometer (NanoDrop Technologies). Reverse transcription of
50 ng total RNA was performed with the iScript cDNA Synthesis
Kit (Bio-Rad) according to themanufacturer’s protocol. Although
fresh prostate tissue was acquired from most patients, tumour
was found in only ten study subjects from the genistein arm
and twelve from the placebo arm.
Semi-quantitative real-time RT PCR
Primers were designed with Primer3 provided by the White-
head Institute for Biomedical Research (http://fokker.wi.mit.
edu/cgibin/primer3/primer3_www.cgi). Sequences are listed
in Table 1. Relative quantiﬁcation of gene expression by
semi-quantitative real-time RT-PCR was performed by analys-
ing the expression of human housekeeping delta-aminolevuli-
nate synthase gene. Real-time PCR was performed on the
Bio-Rad Opticon DNA Engine. All ampliﬁcations were run as
triplicates with standard curves. Here, 1 ng of template was
used in each reaction following the manufacturer’s protocol
(Bio-Rad SYBR Green Master Mix). The same set-up was
used for all primers (sixty-six cycles of 558C annealing, 728C
extension and 908C denaturing).
Tissue processing and immunohistochemical analysis
The prostates were ﬁxed in 10% buffered formalin, macro-
dissected and parafﬁn-embedded. Tissue microarrays were
Table 1. Primers for PCR
Gene Forward primer Reverse primer
AR TGGAAGCTGCAAGGTCTTCT AAGCCTCTCCTTCCTCCTGT
KLK4 ATGGAAAACGAATTGTTCTGCTC CAGCACGGTAGGCATTCTG
NKX3·1 GGCCTGGGAGTCTCTTGACTCCACTAC ATGTGGAGCCCAAACCACAGAAAAATG
p21 AGGGGACAGCAGAGGAAGA CTTCCTGTGGGCGGATTAG
p27 TCAGAAGACGTCAAACGTAAACA CCAACGCTTTTAGAGGCAGA
p53 CCCCAGCCAAAGAAGAAAC TTTTTATGGCGGGAGGTAGA
ALAS1 CTGCAAAGATCTGACCCCTC CCTCATCCACGAAGGTGATT
AR, androgen receptor; KLK4, kallikrein-related peptide 4; NKX3·1, NK3 homeobox 1; p21, cyclin-dependent kinase inhibitor 1A; p27,
cyclin-dependent kinase inhibitor 1B; p53, tumour protein p53; ALASI, aminolevulinate synthase gene.
Table 2. Antibodies for immunohistochemistry
Antigen Clone Supplier Dilution Treatment
AR MS-443 Thermo Scientiﬁc Prediluted Benchmark XT
KLK4 Rabbit F.S lab 3mg/ml Autoclave
NKX3·1 Rabbit F.S lab 1mg/ml Autoclave
p21 EA-10 Calbiochem 0·25mg/ml PT-module*
p27 SC-528 Santa Cruz 1mg/ml PT-Module†
p53 Bp53-11 Roche Prediluted Benchmark XT
Ki67 30-9 Roche Prediluted Benchmark XT
BAX 2D2 Thermo Scientiﬁc 12·5mg/ml PT-module‡
BCL-2 124 Roche Prediluted Benchmark XT
NSE E27 Roche Prediluted Benchmark XT
CgA LK2H10 Roche Prediluted Benchmark XT
AR, androgen receptor; KLK4, kallikrein-related peptide 4; NKX3·1, NK3 homeobox 1;
p21, cyclin-dependent kinase inhibitor 1A; p27, cyclin-dependent kinase inhibitor 1B;
p53, tumour protein p53; BAX, B-cell CLL/lymphoma 2-associated X protein; BCL-2,
B-cell CLL/lymphoma 2; NSE, neuron-speciﬁc enolase; CgA, cytoplasmic chromo-
granin A.
*Citrate buffer pH 6.
† Tris buffer pH 9.
‡EDTA buffer pH 8.
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assembled using the TMABooster (Alphelys) sampler.
Normal, Gleason grade 3 (G3) and Gleason grade 4 (G4), if
available, prostate tumours were marked on haematoxylin/
eosin-stained sections. From each patient, three 0·6mm
biopsy cores were taken from normal prostatic tissue and
each available Gleason grade tumour. The sampling size of
three cores has previously been shown to be representative
of PCa(9). Next, 10mm tissue microarray sections on glass
slides (SuperFrostw) were treated according to the pro-
cedures listed in Table 2. ‘Benchmark XT’ used automated
immunohistochemical staining (Benchmark XT; Ventana
Medical Systems). The slides were treated in a dry cabinet
for 60min at 608C, cooled and washed with a detergent
before conditioning with cell conditioning 1 (CC1) buffer
(Ventana Medical Systems). Detection of the bound primary
antibody was visualised with the iViewe DAB Detection kit
(Ventana Medical Systems). The cells were counterstained
with haematoxylin and Bluing reagent (Ventana Medical Sys-
tems) for 4min. ‘Autoclave’ used citrate buffer pH 6·4 at
1208C for 40min for antigen retrieval. Immunohistochemistry
was performed according to the manufacturer’s protocol
(BioGenex Detection kit). The slides were visualised by dia-
minobenzidine staining followed by haematoxylin staining.
‘PT-module’ used different buffers according to Table 2.
The slides were treated in 988C for 25min in the PT-Module
(Lab Vision Corporation) for antigen retrieval. Immuno-
histochemistry and visualisation were performed according
to the manufacturer’s protocol (UltraVision ONE Detection
System; Thermo Fisher Scientiﬁc). The cells were counter-
stained with haematoxylin. The stained tissues were then
independently analysed by two consultant pathologists
(A. S. and C. H.), who later made a consensus evaluation
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Fig. 1. Expression of androgen-related biomarkers. Real-time RT-PCR of the mRNA expression of (a) androgen receptor (AR), (b) NK3 homeobox 1 (NKX3·1)
and (c) kallikrein-related peptide 4 (KLK4) in laser micro-dissected cells from normal and tumour areas of prostatectomy specimens from patients treated with
either placebo ( ) or genistein ( ). The data were normalised to aminolevulinate synthase gene and are shown as means, with their standard errors. The pro-
tein expression levels of (d) AR, (e) NKX3·1 and (f) KLK4 were determined by immunohistochemical staining of tissue microarrays containing normal and Gleason
grade 3 (G3) and/or Gleason grade 4 (G4) spots of prostatectomy specimens. The ﬁgures show the mean staining intensity, with their standard errors.
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on each sample. Samples not containing the designated
Gleason grade were not analysed and treated as missing.
The staining intensities of nuclear androgen receptor (AR),
cytoplasmic and nuclear NK3 homeobox 1 (NKX3·1),
cytoplasmic kallikrein-related peptide 4 (KLK4), cytoplasmic
and nuclear cyclin-dependent kinase inhibitor 1B (p27Kip1) and
cytoplasmic B-cell CLL/lymphoma 2-associated X protein
(BAX) were scored as either weak/moderate (0) or strong (1),
whereas the staining intensities of cytoplasmic B-cell CLL/
lymphoma 2 (BCL-2), cytoplasmic neuron-speciﬁc enolase
(NSE: also called ENO2) and cytoplasmic chromogranin A (CgA)
were scored as negative (0) or positive cytoplasmic staining (1).
Sample sizes for the placebo arm were: sixteen containing
normal glandular tissue, sixteen G3 and six G4 tumours;
and for the genistein arm: twenty-three normal glandular
tissue, twenty-two G3 and ten G4. In the placebo arm, one
G3 disappeared due to technical reasons for AR and p27Kip1.
In the genistein arm, one G4 disappeared for NKX3·1 and
cyclin-dependent kinase inhibitor 1A (p21Waf1/Cip1).
Statistical analysis
Values are expressed as means with their standard errors for
continuous and ordinal data. Differences between two related
and independent samples were tested by Fisher–Pitman per-
mutation tests for paired and two-sample interval-scaled data.
The P-values were based on 2000 simulations and considered
signiﬁcant at P,0·050. The analyses were carried out in
STATA/IC 11.1 for Windows (32-bit) and Sigmaplot 11.0 for
Windows was used to create the ﬁgures.
Results
Androgen-related biomarkers
Genistein intervention signiﬁcantly reduced KLK4 mRNA
expression in tumour cells (P¼0·033). The down-regulation
of AR protein expression and KLK4 mRNA level in normal
cells were not statistically signiﬁcant (P¼0·123 and P¼0·087;
Fig. 1(c) and (d)). There was a general non-signiﬁcant ten-
dency by genistein intervention to reduce the expression of
androgen-related biomarkers (Fig. 1).
The AR and NKX3·1 nuclear protein expression in both
study arms were reduced in higher Gleason grades, whereas
both the mRNA and protein expression were increased for
KLK4. AR mRNA expression was unchanged. Fig. 2(a) depicts
a patient treated with placebo showing strong nuclear AR
staining intensity in normal cells and weak intensity in the
case of tumour. The cytoplasmic expression of NKX3·1 was
equivalently increased (data not shown). Fig. 2(b) shows a
patient from the genistein group with strong nuclear/weak
cytoplasmic NKX3·1 staining intensity in normal cells and
weak nuclear/strong cytoplasmic staining intensity in
tumour. Fig. 2(c) depicts a patient treated with genistein show-
ing weak cytoplasmic KLK4 staining intensity in normal cells
and strong intensity in tumour.
Cell cycle-related biomarkers
Genistein intervention had no signiﬁcant effects on p21Waf1/Cip1,
p27Kip1 or tumour protein p53 (p53) mRNA and protein
expression (Fig. 3). There was a non-signiﬁcant reduction in
(a)
(b)
(c)
Normal G3 G4
Fig. 2. Immunohistochemical staining of androgen-related biomarkers. Each row shows tissue microarray spots from a single patient containing normal, Gleason
grade 3 (G3) and Gleason grade 4 (G4) prostate tissues. Encircled areas contain designated Gleason grade. Magniﬁcation £400. (a) Androgen receptor,
(b) NK3 homeobox 1 and (c) kallikrein-related peptide 4.
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the expression of p21Waf1/Cip1 mRNA expression in tumour
(P¼0·184) and a slight reduction in p27Kip1 and p53 mRNA
expression, whereas 27kip1 protein nuclear expression was
slightly increased in G3 and G4 in the genistein arm compared
with placebo.
The mRNA and protein expression results for the cell
cycle-related biomarkers were coherent in both study arms,
showing increased levels of p21Waf1/Cip1 and p53 and reduced
levels of p27Kip1 in tumour tissue compared to normal tissue.
The percentage p21Waf1/Cip1 positive cells was less than 1% in
normal prostate tissue and increased with increasing Gleason
grade to about 2% in G3 cells and 4% in G4 cells. Fig. 4(a)
depicts a patient from the genistein group showing an increas-
ing number of p21Waf1/Cip1 positive nuclei from normal tissue
to G4. The nuclear expression of p27Kip1 was signiﬁcantly
reduced in G3 (P¼0·016) compared to normal, whereas the
mRNA level was non-signiﬁcantly reduced in tumour com-
pared to normal cells (Fig. 3(b) and (e)). Fig. 4(b) shows a
patient from the placebo group with strong nuclear/weak
cytoplasmic staining intensity in normal cells and weak
nuclear/strong cytoplasmic p27Kip1 staining in G3. Fig. 4(c)
shows a patient treated with placebo with no p53 positive
cells in normal tissue and with single p53 positive cells in
G3 and G4 tissues.
Proliferation- and apoptosis-related biomarkers
Genistein intervention had no signiﬁcant effects on the protein
expression of Ki67, BAX or BCL-2 (Fig. 5).
In both study arms, Ki67 and BAX expression increased
with increasing Gleason grade. Ki67 was expressed by 1%
of normal epithelial cells and it increased signiﬁcantly to 3%
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Fig. 3. Expression of cell cycle-related biomarkers. Real-time RT-PCR of the mRNA expression of (a) cyclin-dependent kinase inhibitor 1A (p21Waf1/Cip1),
(b) cyclin-dependent kinase inhibitor 1B (p27Kip1) and (c) tumour protein p53 (p53) in laser micro-dissected cells from normal and tumour areas of prostatectomy
specimens from patients treated with either placebo ( ) or genistein ( ). The data were normalised to aminolevulinate synthase gene and are shown as
means, with their standard errors. The protein expression level of (d) p21Waf1/Cip1, (e) p27Kip1 and (f) p53 was determined by immunohistochemical staining of
tissue microarrays containing normal and Gleason grade 3 (G3) and/or Gleason grade 4 (G4) spots of prostatectomy specimens. The ﬁgures show the mean
staining intensity or percentage positive cells, with their standard errors.
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in G3 cells (P,0·001) and further to approximately 5% in
G4 cells (Fig. 5(a)). Fig. 6(a) depicts a patient treated with
genistein showing increasing number of Ki67 positive cells
from normal tissue to G4. BAX protein expression increased
signiﬁcantly (P¼0·011) in G3 compared to normal cells
(Fig. 5(b)). Fig. 6(b) shows a patient treated with genistein
with weak cytoplasmic BAX staining in normal tissue and
increasing intensity in tumour tissue. BCL-2 was in general
not expressed in normal epithelial cytoplasm (Fig. 5(c)). The
increased expression in malignant tissue was not statistically
(a)
(b)
(c)
Normal G3 G4
Fig. 4. Immunohistochemical staining of cell cycle-related biomarkers. Each row shows tissue microarray spots from a single patient containing normal, Gleason
grade 3 (G3) and/or Gleason grade 4 (G4) prostate tissues. Magniﬁcation £400 for (a) cyclin-dependent kinase inhibitor 1A and (b) cyclin-dependent kinase
inhibitor 1B. Magniﬁcation £600 for (c) tumour protein p53.
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Fig. 5. Expression of proliferation- and apoptosis-related biomarkers. The protein expression of (a) Ki67, (b) B-cell CLL/lymphoma 2-associated X protein and
(c) B-cell CLL/lymphoma 2 was determined by immunohistochemical staining of tissue microarrays containing normal and Gleason grade 3 (G3) and/or Gleason
grade 4 (G4) spots of prostatectomy specimens. The ﬁgures show the mean staining intensity or percentage positive cells, with their standard errors. , Placebo;
, genistein.
B. Lazarevic et al.6
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
signiﬁcant (P¼0·125). Fig. 6(b) shows a patient treated
with genistein with weak BCL-2 staining in normal tissue
and stronger staining in tumour tissue.
Neuroendocrine differentiation-related biomarkers
Genistein intervention had no signiﬁcant effect on NSE or
CgA (Fig. 7).
In both study arms, the expression of the neuroendocrine
differentiation-related biomarkers indicated reduced levels
with increasing Gleason grade. Fig. 8(a) shows a patient trea-
ted with placebo with decreasing number of NSE-positive cells
in G3 tumour. There was a clear presence of CgA-positive
cells in normal tissue, which was completely abolished in
G4 tissue in both treatment arms (P,0·001; Fig. 7(b)).
Fig. 8(b) shows a patient treated with genistein with decreas-
ing number of CgA-positive cells with higher Gleason grade.
Discussion
To our knowledge, this is the ﬁrst study which exclusively
investigates the effects by genistein alone in men with PCa.
We showed that genistein intervention signiﬁcantly down-
regulated the mRNA expression levels of KLK4 in cancer
cells in men with localised PCa. Genistein has previously
been shown to decrease AR nuclear binding to the transcrip-
tional binding site for AR(10). We also report a decrease by
genistein on most of the selected androgen-related bio-
markers, corroborating the results of our in vitro studies(11).
However, the average plasma level in the present study was
at least 25-fold lower than the concentrations used in cell cul-
ture studies, indicating that in vivo nutritional relevant levels
of genistein may have comparable effects to high-dose cell
studies. This may be related to longer in vivo exposure. The
androgen-related biomarkers used in this study have been
attributed roles in the development or progression of PCa.
NKX3·1 is an androgen-regulated homeobox gene located
Normal
(c)
(b)
(a)
G3 G4
Fig. 6. Immunohistochemical staining of proliferation- and apoptosis-related biomarkers. Each row shows tissue microarray spots from a single patient containing
normal, Gleason grade 3 (G3) and Gleason grade 4 (G4) prostate tissues. Magniﬁcation £400. (a) Ki67, (b) B-cell CLL/lymphoma 2-associated X protein and
(c) B-cell CLL/lymphoma.
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Fig. 7. Expression of neuroendocrine differentiation-related biomarkers. The
protein expression of (a) neuron-speciﬁc enolase and (b) cytoplasmic chromo-
granin A was determined by immunohistochemical staining of tissue microar-
rays containing normal and Gleason grade 3 (G3) and/or Gleason grade 4
(G4) spots of prostatectomy specimens. The ﬁgures show the mean positive/
negative stain, with their standard errors. , Placebo; , genistein.
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on chromosome 8p21·2, a region that shows a high degree of
loss of heterozygosity in PCa(12,13). Reports of its function and
expression in PCa have been conﬂicting. However, most
reports indicate that NKX3·1 acts as a non-classical tumour
suppressor and that its expression is reduced in primary
PCa and further reduced in metastatic PCa(14,15). However,
our immunohistochemistry results indicated a translocation
of NKX3·1 from the nucleus to the cytoplasm and not a total
reduction with increasing Gleason grade. Interestingly,
increased cytoplasmic stain intensity in primary PCa was
brieﬂy mentioned by Gurel et al.(15), although it was not
taken into account during scoring. Different splicing variants
of NKX3·1 and antibodies have previously been attributed
for the conﬂicting results of NKX3·1 expression. Human
kallikrein 4 (KLK4), a serine protease belonging to the
prostate speciﬁc antigen-related kallikrein family, is over-
expressed in PCa and might be a proliferative factor acting
directly or indirectly on cell cycle regulators(16). Increased
KLK4 levels in PC-3 cells have also been associated with
a transcriptional repression of E-cadherin and increased
Matrigel motility(17). Our results were consistent with previous
reports showing an overexpression of KLK4 mRNA and
protein in PCa.
There are no previous reports on in vivo studies on the effects
of genistein on the cell cycle-related genes p21 Waf1/Cip1, p27 Kip1
and p53. However, in vitro studies on prostate, breast and
lung cancer cells report that genistein up-regulates them, in
line with its inhibitory effect on cell cycle progression(18,19).
We did not observe any signiﬁcant effects by genistein,
but the mRNA levels of p21Waf1/Cip1, p27Kip1 and p53 were
slightly down-regulated. The reason for this discrepancy is
not clear. Interestingly, we showed an increased expression
of p21Waf1/Cip1 and p53 mRNA and protein expression in G3
and that the expression may further increase with increasing
Gleason grade. Navone et al.(20) showed that p53 accu-
mulation is associated with late-stage PCa. With a cutoff
value at 5% of p53 positive cells, they detected no accumu-
lation in nineteen patients with Gleason score 5–7, whereas
nineteen of forty-two patients with Gleason score 8–10
showed accumulation. p21Waf1/Cip1 may act both as a cell
cycle negative regulator and anti-apoptotic mediator and its
protein expression has been shown to correlate strongly
with p53 in PCa(21,22). The reduction of p27Kip1 mRNA and
nuclear protein expression in both study arms and the small
reversal of protein expression in G3 and G4 by genistein
intervention may have an interesting implication for the cell
cycle modulating properties of genistein. Loss of phosphatase
and tensin homologue function and/or constitutive acti-
vation of Akt/protein kinase B by the phosphoinositide
kinase-3 pathway, commonly found in PCa, will reduce
the expression of p27Kip1 (23,24). In vitro studies on genistein
indicate that it inhibits protein kinase B constitutive activation
by re-establishing phosphatase and tensin homologue
expression(25,26). Although the increase of p27kip1 in G3 and
G4 by genistein was not signiﬁcant, this result may indicate
the mechanism for its G1 cell cycle arrest and proliferation
inhibition of tumour cells(27). Further research is needed
in this connection.
The proliferation biomarker Ki67 was clearly up-regulated
in tumour tissue, although it was not modulated by genistein.
Our detection of 1% Ki67 positive luminal cells in normal
and 4–6% in tumour tissue corroborates with previous
publications(28). The increasing levels of Ki67, p21Waf1/Cip1
and p53 may indicate that loss of p53 function already is
present in some G3 cancers.
The apoptotic biomarkers BAX and BCL-2 were both signiﬁ-
cantly or near-signiﬁcantly up-regulated in PCa, corroborating
a previous report on Gleason score 5–10(29). We observed no
signiﬁcant regulation of BAX or BCL-2 by genistein
intervention.
The role of neuroendocrine markers as prognostic factors is
controversial, although the serum level of CgA and NSE seems
to have a prognostic value in castration-resistant PCa(30–32).
Genistein treatment of LNCaP human prostatic adenocarci-
noma cells has been shown to induce several positive bio-
markers for neuroendocrine differentiation including CgA(19).
We detected very few CgA- and NSE-positive cells in tumour
tissue. The reduction of CgA-positive cells in tumour tissue
corroborates earlier results from serum, showing a reduction
in localised PCa and an increase in castration-resistant PCa(31).
The ability of genistein to modulate the progression of exist-
ing PCa is not clear. In the present study, we have investigated
the effects of pure genistein. As opposed to the majority of
chemopreventive reports of genistein treatment, some recent
studies on mouse xenograft models indicate genistein to pro-
mote increased metastasis of PCa, whereas isoﬂavones con-
taining genistein and daidzein do not(33–37). Other studies
show that dietary genistein inhibits metastases of human
cancer, including PCa, in mice and that the discrepancy may
be related to methodology(38,39). In addition, Setchell et al.(40)
raised doubts about the use of rodent models for gaining
insight into the effect of isoﬂavones in humans due to differ-
ences in the metabolism of genistein. We did not detect any
signs of cancer-promoting effects in our study with pure
Normal
(a)
(b)
G3
Fig. 8. Immunohistochemical staining of neuroendocrine differentiation-
related biomarkers. Both rows show tissue microarray spots from the
same patient containing normal and Gleason grade 3 (G3) prostate tissues.
Magniﬁcation £400. (a) neuron-speciﬁc enolase and (b) cytoplasmic
chromogranin A.
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genistein intervention in our human study subjects having
early localised PCa.
Overall, genistein intervention at nutritionally relevant
levels in patients with early PCa modulated several biomarkers
which may be related to cancer prediction and progression.
Genistein may have an inhibitory effect on androgen-related
biomarkers. We also suggest a possible mechanism as to
how genistein may induce cell cycle arrest and inhibition of
proliferation in PCa. A limitation in our study is the small
number of cases included and also the relative short time of
intervention. Further studies on the effects of genistein in
PCa are warranted, including clinical studies examining bio-
markers and in vitro studies investigating its mechanisms of
action.
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